+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab



Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab



Journal of Clinical Oncology 31(6): 759-765



Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has demonstrated significant improvements in progression-free survival (PFS) in patients with wild-type KRAS metastatic colorectal cancer (mCRC) in studies 20050203 (first line), 20050181 (second line), and 20020408 (monotherapy). Mutations in KRAS codons 12 and 13 are recognized biomarkers that predict lack of response to anti-EGFR antibody therapies. This retrospective analysis of three randomized phase III studies assessed the prognostic and predictive impact of individual mutant KRAS codon 12 and 13 alleles. Patients were randomly assigned 1:1 to FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) in study 20050203, FOLFIRI (fluorouracil, leucovorin, and irinotecan) in study 20050181, or best supportive care in study 20020408 with or without panitumumab 6.0 mg/kg once every 2 weeks. In all, 441 (20050203), 486 (20050181), and 126 (20020408) patients with mutant KRAS codon 12 or 13 alleles were included in the analysis. No mutant KRAS allele in patients treated on the control arm emerged as a consistent prognostic factor for PFS or overall survival (OS). In addition, no mutant KRAS allele was consistently identified as a predictive factor for PFS or OS in patients receiving panitumumab treatment. Significant interactions for individual mutant KRAS alleles were observed only in study 20050203 with G13D negatively and G12V positively associated with OS in the panitumumab-containing arm. Pooled analysis indicated that only G12A was associated with a negative predictive effect on OS. In this retrospective analysis, results across three treatment regimens suggest that patients with mutant KRAS codon 12 or 13 mCRC tumors are unlikely to benefit from panitumumab therapy. Currently, panitumumab therapy should be limited to patients with wild-type KRAS mCRC.

(PDF emailed within 0-6 h: $19.90)

Accession: 054512740

Download citation: RISBibTeXText

PMID: 23182985

DOI: 10.1200/JCO.2012.45.1492


Related references

Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer. International Journal of Colorectal Disease 26(10): 1353-1354, 2012

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Research 36(9): 4955-4959, 2017

Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients. Anti-Cancer Drugs 26(8): 872-877, 2015

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. Cancer Biology and Therapy 14(12): 1098-1103, 2015

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clinical Cancer Research 20(16): 4240-4250, 2015

The KRAS p.G13D mutation in patients with metastatic colorectal cancer: a cheat in the orchestra of predictive biomarkers?. Gastroenterology 141(4): 1527-1528, 2011

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. European Journal of Cancer 46(15): 2781-2787, 2011

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therapeutic Advances in Gastroenterology 7(1): 20-37, 2014

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours. European Journal of Cancer 51(11): 1371-1380, 2015

Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy. EJC Supplements 5(6): 8, 2007

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 26(10): 1626-1634, 2008

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Yearbook of Pathology and Laboratory Medicine 2009: 213-214, 2009

Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. Japanese Journal of Clinical Oncology 41(2): 210-216, 2011

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Oncotargets and Therapy 9: 75-86, 2016

Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab. Journal of the National Comprehensive Cancer Network 15(4): 427-432, 2017